New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer – What do we understand so far?

Jean Hoffman-Censits; Kara Lombardo; David McConkey; Noah M. Hahn; Babar Bashir; Wm Kevin Kelly; Burles Johnson; Andres Matoso

doi:10.1016/j.urolonc.2021.05.013

New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer – What do we understand so far?

Jean Hoffman-Censits, Kara Lombardo, David McConkey, Noah M. Hahn, Babar Bashir, Wm Kevin Kelly, Burles Johnson, Andres Matoso

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum- and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortumab is an antibody-drug conjugate that targets Nectin-4, which is widely expressed in urothelial cancer. Despite this ample target, clinical benefit is not achieved by all patients, and mechanisms of treatment resistance are undescribed. Herein we summarize what is known to date regarding coorelative findings and subgroup analysis and EV response, including novel biopsy data in patients with tumor progression post EV.

Original language	English (US)
Pages (from-to)	619-622
Number of pages	4
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	39
Issue number	10
DOIs	https://doi.org/10.1016/j.urolonc.2021.05.013
State	Published - Oct 2021

Keywords

Bladder cancer
Enfortumab vedotin
Nectin-4
Upper tract urothelial cancer

ASJC Scopus subject areas

Urology
Oncology

Access to Document

10.1016/j.urolonc.2021.05.013

Cite this

Hoffman-Censits, J, Lombardo, K, McConkey, D , Hahn, NM, Bashir, B, Kelly, WK, Johnson, B & Matoso, A 2021, 'New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer – What do we understand so far?', Urologic Oncology: Seminars and Original Investigations, vol. 39, no. 10, pp. 619-622. https://doi.org/10.1016/j.urolonc.2021.05.013

@article{32bffc2ce7334054a392a2e31b9f3840,

title = "New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer – What do we understand so far?",

abstract = "Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum- and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortumab is an antibody-drug conjugate that targets Nectin-4, which is widely expressed in urothelial cancer. Despite this ample target, clinical benefit is not achieved by all patients, and mechanisms of treatment resistance are undescribed. Herein we summarize what is known to date regarding coorelative findings and subgroup analysis and EV response, including novel biopsy data in patients with tumor progression post EV.",

keywords = "Bladder cancer, Enfortumab vedotin, Nectin-4, Upper tract urothelial cancer",

author = "Jean Hoffman-Censits and Kara Lombardo and David McConkey and Hahn, {Noah M.} and Babar Bashir and Kelly, {Wm Kevin} and Burles Johnson and Andres Matoso",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = oct,

doi = "10.1016/j.urolonc.2021.05.013",

language = "English (US)",

volume = "39",

pages = "619--622",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - New and topics

T2 - enfortumab vedotin mechanisms of response and resistance in urothelial cancer – What do we understand so far?

AU - Hoffman-Censits, Jean

AU - Lombardo, Kara

AU - McConkey, David

AU - Hahn, Noah M.

AU - Bashir, Babar

AU - Kelly, Wm Kevin

AU - Johnson, Burles

AU - Matoso, Andres

PY - 2021/10

Y1 - 2021/10

N2 - Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum- and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortumab is an antibody-drug conjugate that targets Nectin-4, which is widely expressed in urothelial cancer. Despite this ample target, clinical benefit is not achieved by all patients, and mechanisms of treatment resistance are undescribed. Herein we summarize what is known to date regarding coorelative findings and subgroup analysis and EV response, including novel biopsy data in patients with tumor progression post EV.

AB - Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum- and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortumab is an antibody-drug conjugate that targets Nectin-4, which is widely expressed in urothelial cancer. Despite this ample target, clinical benefit is not achieved by all patients, and mechanisms of treatment resistance are undescribed. Herein we summarize what is known to date regarding coorelative findings and subgroup analysis and EV response, including novel biopsy data in patients with tumor progression post EV.

KW - Bladder cancer

KW - Enfortumab vedotin

KW - Nectin-4

KW - Upper tract urothelial cancer

UR - http://www.scopus.com/inward/record.url?scp=85110122096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85110122096&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2021.05.013

DO - 10.1016/j.urolonc.2021.05.013

M3 - Article

C2 - 34148797

AN - SCOPUS:85110122096

SN - 1078-1439

VL - 39

SP - 619

EP - 622

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

IS - 10

ER -

New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer – What do we understand so far?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this